Trials / Completed
CompletedNCT05075772
A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
Absolute Bioavailability, Safety, Tolerability, and Pharmacodynamics Following Subcutaneous (SC) Injection of 100 mg BI 765080 Relative to Intravenous (IV) Dose in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A study in healthy man to investigate the absolute bioavailability of 100mg BI 765080, once administered as subcutaneous (SC) injection and once administered as intravenous infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 765080 | BI 765080 |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2022-03-11
- Completion
- 2022-03-11
- First posted
- 2021-10-13
- Last updated
- 2024-08-13
- Results posted
- 2024-08-13
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05075772. Inclusion in this directory is not an endorsement.